GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Tax Provision

UPB (Upstream Bio) Tax Provision : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Tax Provision?

Upstream Bio's tax provision for the three months ended in Sep. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Upstream Bio Tax Provision Historical Data

The historical data trend for Upstream Bio's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Tax Provision Chart

Upstream Bio Annual Data
Trend Dec22 Dec23
Tax Provision
- -

Upstream Bio Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Tax Provision Get a 7-Day Free Trial - - - - -

Upstream Bio Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Tax Provision
Comparable Companies
Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Website
https://www.upstreambio.com
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.